Proqr Therapeutics NV

Boer Daniel Anton De, Chief Executive Officer and a Director of ProQR Therapeutics N.V., purchased 200,000 shares of common stock on July 31, 2026 for $1.77 per share.

Bart Filius, a Director of ProQR Therapeutics N.V., purchased 150,000 shares of common stock on July 17, 2026 for $1.72 per share.

Boer Daniel Anton De, Chief Executive Officer and a Director of ProQR Therapeutics N.V., purchased 150,000 shares of common stock on July 9, 2026 for $1.74 per share.

ProQR Therapeutics N.V. reports a significant share purchase by its CEO and Director, Daniel Anton de Boer.

ProQR Therapeutics N.V. files an amended Form 4 to correct the number of share options reported for Director Gylvin Lykke Hinsch.

ProQR Therapeutics N.V. reports a significant share acquisition by Director Bart Filius.

Van Herk Investments and other shareholders have filed a petition with the Dutch Enterprise Chamber seeking an investigation into ProQR Therapeutics' corporate governance and requesting the appointment of an independent director.

Van Herk Investments B.V. and affiliated entities have updated their Schedule 13D filing, reporting a 10.9% ownership in ProQR Therapeutics N.V. following a recent share issuance.

Van Herk Investments B.V. announced its intention to vote against key share capital increase and authorization proposals at ProQR Therapeutics N.V.'s upcoming Annual General Meeting, citing concerns over potential dilution and governance.

Van Herk Investments B.V. and its affiliates have increased their beneficial ownership in ProQR Therapeutics N.V. to 14.6% through recent open market purchases.

Van Herk Investments B.V. and its affiliated entities have increased their beneficial ownership in ProQR Therapeutics N.V. to 13.6% through recent open market purchases.

Van Herk Investments B.V. and its affiliates have increased their beneficial ownership in ProQR Therapeutics N.V. to 12.6% through recent open market purchases.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 6.33% in ProQR Therapeutics NV's ordinary shares.

Eli Lilly and Company has reported a significant beneficial ownership stake of 15.6% in ProQR Therapeutics N.V., holding 21,995,880 ordinary shares.

Several entities and an individual have updated their beneficial ownership filings for ProQR Therapeutics N.V. ordinary shares, collectively holding a significant stake.

Multiple Dutch investment entities and their portfolio manager have disclosed passive beneficial ownership stakes in ProQR Therapeutics N.V., with Privium Fund Management B.V. and Patrick Johan Hendrik Krol each holding 5.2%.

Adage Capital Management, L.P. and its principals have disclosed a 6.27% beneficial ownership stake in ProQR Therapeutics N.V. as of June 30, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 7.70% of ProQR Therapeutics N.V.'s Ordinary Shares as of March 31, 2025.